METHYLPREDNISOLONE ENHANCES THE EFFICACY OF ONDANSETRON IN ACUTE AND DELAYED CISPLATIN-INDUCED EMESIS OVER AT LEAST 3 CYCLES

被引:34
作者
CHEVALLIER, B
MARTY, M
PAILLARSE, JM
机构
[1] LABS GLAXO,DEPT MED,PARIS,FRANCE
[2] HOP ST LOUIS,PARIS,FRANCE
关键词
D O I
10.1038/bjc.1994.467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This double-blind multicentre study has been carried out in order to confirm the improvement of ondansetron's antiemetic efficacy when combined with a corticosteroid and to determine whether this increased efficacy is maintained over three chemotherapy courses. One hundred and two patients receiving their first course of cisplatin (50-120 mg m(-2))-containing chemotherapy were randomised to receive one of the two following treatments: 8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed 8-12 h later by an 8 mg OND tablet and a 16 mg MPD tablet (oral treatment administered twice daily for 3-5 days); or 8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8-12 h later by an 8 mg OND tablet and placebo p.o. (oral treatment administered twice daily for 3-5 days). The number of emetic episodes (EEs = vomits + retches) and the grade of nausea were recorded. Of the 101 patients studied (efficacy analysis), complete or major control (0-2 EEs) was experienced in 90.4% of patients in the first 24 h in the OND/MPD group compared with 71.4% of patients in the OND group during the first course. This difference in favour of OND/MPD was noted over the three courses and is statistically significant. In the control of delayed emesis (worst day between days 2 and 6) there is a trend in favour of the OND/MDP group during the first course [56.2% vs 43.2% for complete response (no emetic episodes)] which was statistically significant on courses 2 and 3. The global antiemetic control over the course was always in favour of OND/MPD, which leads to a better efficacy maintained over the three courses. Both treatments were well tolerated. The results of this study confirm the increased antimetic efficacy of ondansetron and methylprednisolone in combination in cisplatin-induced acute and delayed emesis which led to a better maintained efficacy over three repeated chemotherapy courses.
引用
收藏
页码:1171 / 1175
页数:5
相关论文
共 17 条
[1]  
CLAVEL M, 1991, CAH CANC, V3, P7
[2]   Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting - A Multicenter, Randomized, Double-Blind, Crossover Study [J].
Demulder, PHM ;
Seynaeve, C ;
Vermorken, JB ;
Vanliessum, PA ;
Molsjevdevic, S ;
Allman, EL ;
Beranek, P ;
Verweij, J .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (11) :834-840
[3]  
Dicato M A, 1992, Clin Oncol (R Coll Radiol), V4, P275, DOI 10.1016/S0936-6555(05)81098-2
[4]   A SINGLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON, A SELECTIVE SEROTONIN ANTAGONIST, WITH INTRAVENOUS METOCLOPRAMIDE IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE CISPLATIN CHEMOTHERAPY [J].
HAINSWORTH, J ;
HARVEY, W ;
PENDERGRASS, K ;
KASIMIS, B ;
OBLON, D ;
MONAGHAN, G ;
GANDARA, D ;
HESKETH, P ;
KHOJASTEH, A ;
HARKER, G ;
YORK, M ;
SIDDIQUI, T ;
FINN, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) :721-728
[5]  
HELLENBRECHT D, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1845
[6]   CONTROLLING DELAYED VOMITING - DOUBLE-BLIND, RANDOMIZED TRIAL COMPARING PLACEBO, DEXAMETHASONE ALONE, AND METOCLOPRAMIDE PLUS DEXAMETHASONE IN PATIENTS RECEIVING CISPLATIN [J].
KRIS, MG ;
GRALLA, RJ ;
TYSON, LB ;
CLARK, RA ;
CIRRINCIONE, C ;
GROSHEN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :108-114
[7]  
KRIS MG, 1985, CANCER, V55, P527, DOI 10.1002/1097-0142(19850201)55:3<527::AID-CNCR2820550310>3.0.CO
[8]  
2-2
[9]   COMPARISON OF THE 5-HYDROXYTRYPTAMINE3 (SEROTONIN) ANTAGONIST ONDANSETRON (GR-38032F) WITH HIGH-DOSE METOCLOPRAMIDE IN THE CONTROL OF CISPLATIN-INDUCED EMESIS [J].
MARTY, M ;
POUILLART, P ;
SCHOLL, S ;
DROZ, JP ;
AZAB, M ;
BRION, N ;
PUJADELAURAINE, E ;
PAULE, B ;
PAES, D ;
BONS, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (12) :816-821
[10]  
MARTY M, 1990, CAHIERS CANCER, V2, P541